Citi raised the firm’s price target on Merus (MRUS) to $97 from $89 and keeps a Buy rating on the shares after petosemtamab monotherapy data in second-line and later head and neck squamous cell carcinoma was presented at ESMO Asia this weekend. The “substantive” monotherapy data demonstrated about a 36% ORR as of the July 5 cutoff date and was largely consistent with prior cuts shared at AACR 2023, notes the analyst, who says the new data “provides a significantly higher level of conviction” that 1500 mg is the right choice for both first-line and second-line Phase 3 work and that the monotherapy profile is now well-established from both an efficacy and safety perspective.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRUS:
- 3 Best Stocks to Buy Now, 12/6/2024, According to Top Analysts
- Merus gets FDA approval of BIZENGRI in NRG1+ Pancreatic Adenocarcinoma, NSCLC
- Merus’ zenocutuzumab-zbco granted accelerated approval by FDA
- Merus price target lowered to $109 from $111 at Guggenheim
- Merus, Partner Therapeutics enter agreement for Zenocutuzumab commercialization